What we’re tracking.
A running log of regulatory developments, research summaries, and industry movement across the peptide space. The full briefings go out by email — subscribe to get them as they land.
- RegulatoryJune 2026
Counting down to the July compounding committee meeting
The FDA Pharmacy Compounding Advisory Committee is scheduled to meet July 23–24, 2026 to review nominated substances relevant to the compounding lists — peptides among them. What the meeting is, why it matters, and exactly what we'll be watching for.
- ExplainerJune 2026
503A vs. 503B: why the distinction keeps coming up
Two sections of federal law govern pharmacy compounding, and the difference between them shapes what can be made and how. A plain-language primer on the landscape — no recommendations, just how the pieces fit together.
- ResearchMay 2026
How to read a peptide study without getting spun
Emerging research gets summarized in a lot of misleading ways. A short, practical guide to separating what a study actually shows from what tends to get claimed about it online.
Get new entries in your inbox.
Subscribe to the briefing and join the priority waitlist.
News & information only · Not medical advice
News & Information — Not Medical Advice
AetherPeptide is an independent news and information service covering peptide research and regulatory developments. We are not a pharmacy, drug manufacturer, or healthcare provider, and nothing here is medical advice. All content is for general informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Joining the newsletter or waitlist is not a purchase and does not create a patient–provider relationship. “Priority access” refers only to future, compliant options should they become available following regulatory clarity.